Compare Crispr Therapeutics AG (CRSP) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kingsoft Cloud Holdings Limited — how do they compare? Crispr Therapeutics AG trades at $53.84 (market cap $5.23B), while Kingsoft Cloud Holdings Limited trades at $11.66 (market cap $3.53B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap. Which is the better fit depends on your goals.
| CRSP | KC | |
|---|---|---|
Market Cap | $5.23B | $3.53B |
Sector | Health | Technology |
52-Week High | $76.78 | $18.21 |
52-Week Low | $44.34 | $8.58 |
Enterprise Value | $3.65B | $3.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Kingsoft Cloud (KC) trades at $11.66, down 2.55% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue growth of 37% year-over-year in Q1 2026, driven by AI cloud services, but net income remains negative at -$936 million for 2025. Analyst consensus is strongly bullish with 70% buy ratings, citing AI-driven expansion and undervaluation relative to peers.
The outlook is positive due to AI revenue acceleration and analyst optimism, but risks include persistent losses, high capital expenditure, and competitive pressures in China's cloud market. Investors should weigh growth potential against profitability challenges ahead of Q2 2026 earnings on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
